These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

847 related items for PubMed ID: 24347095

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection.
    Osterholzer DA, Goldman M.
    Clin Infect Dis; 2014 Jul 15; 59(2):265-71. PubMed ID: 24723281
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.
    Park TE, Mohamed A, Kalabalik J, Sharma R.
    Expert Rev Anti Infect Ther; 2015 Jul 15; 13(10):1195-212. PubMed ID: 26293294
    [Abstract] [Full Text] [Related]

  • 6. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
    Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S, SPRING-2 Study Group.
    Lancet; 2013 Mar 02; 381(9868):735-43. PubMed ID: 23306000
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV.
    Kandel CE, Walmsley SL.
    Drug Des Devel Ther; 2015 Mar 02; 9():3547-55. PubMed ID: 26185421
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Adverse drug reactions to integrase strand transfer inhibitors.
    Lepik KJ, Yip B, Ulloa AC, Wang L, Toy J, Akagi L, Lima VD, Guillemi S, Montaner JSG, Barrios R.
    AIDS; 2018 Apr 24; 32(7):903-912. PubMed ID: 29424784
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.
    Malet I, Thierry E, Wirden M, Lebourgeois S, Subra F, Katlama C, Deprez E, Calvez V, Marcelin AG, Delelis O.
    J Antimicrob Chemother; 2015 Oct 24; 70(10):2870-80. PubMed ID: 26205139
    [Abstract] [Full Text] [Related]

  • 14. Integrase strand transfer inhibitors in the management of HIV-positive individuals.
    Mesplède T, Quashie PK, Zanichelli V, Wainberg MA.
    Ann Med; 2014 May 24; 46(3):123-9. PubMed ID: 24579911
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
    Ndashimye E, Avino M, Olabode AS, Poon AFY, Gibson RM, Li Y, Meadows A, Tan C, Reyes PS, Kityo CM, Kyeyune F, Nankya I, Quiñones-Mateu ME, Arts EJ.
    J Antimicrob Chemother; 2020 Dec 01; 75(12):3525-3533. PubMed ID: 32853364
    [Abstract] [Full Text] [Related]

  • 19. New first and second generation inhibitors of human immunodeficiency virus-1 integrase.
    Pendri A, Meanwell NA, Peese KM, Walker MA.
    Expert Opin Ther Pat; 2011 Aug 01; 21(8):1173-89. PubMed ID: 21599420
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.